Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Competitive Outlook on Non-Antibody Based Cancer Vaccines

Published by: BioSeeker Group AB

Published: Aug. 3, 2006



Table of Contents


1 Executive Summary




2 Cancer Highlights




3 Methodology




4 Table of Contents

4.1 List of Boxes

4.2 List of Figures

4.3 List of Tables




5 Vaccine Strategies: Challenges & Opportunities




6 Competitive Landscape in Cancer Vaccines

6.1 Countries & Players: Who are In the Lead?


6.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not Included!

6.1.2 Approved Cancer Vaccine Drugs: Performance


6.2 Deals & Alliances in Cancer Vaccines


6.2.1 Recent Mergers & Acquisitions in Cancer Vaccines

6.2.2 Deals in Prostate Cancer

6.2.3 Deals in Breast Cancer

6.2.4 Deals in Leukemia & Lymphoma

6.2.5 Drug Delivery Deals in Cancer Vaccines

6.2.6 Adjuvant Deals




7 Tumor Antigens

7.1 Tumor Antigens: General Comments

7.2 Antigen Discovery


7.2.1 Classical Immunology Approach

7.2.2 The Reverse Immunology Approach

7.2.3 Company Platforms


7.2.3.1 Epitope Identification System - EIS®

7.2.3.2 EPIQUEST system

7.2.3.3 MolecularBreeding™ & MaxyScan™

7.2.3.4 ProtEx™ technology

7.2.3.5 Rapid Identification of Alternative Splicing (RIAS) System

7.2.3.6 SMARTOMICS™



7.3 Specific Antigen Processing Technologies Increasing Antigen Presentation




8 Immunomodulators & Adjuvants in Cancer Vaccines

8.1 Overview

8.2 Cytokines


8.2.1 Vaccines in Combination with Interleukin-2

8.2.2 Tumor Necrosis Factor

8.2.3 Interferons


8.3 Adjuvants

8.4 Other Immunomodulating Strategies


8.4.1 An Immune Response Modifying Protein

8.4.2 Immunostimulatory DNA

8.4.3 Ex Vivo Stimulated Immune Cells

8.4.4 Fusion Protein Gain Potent Immune Response

8.4.5 Macrophage and Natural Killer Cells Activation

8.4.6 Selective Suppression of the Immune System to An Antigen

8.4.7 TAP Technology




9 Cancer Vaccine Delivery

9.1 Viral Delivery


9.1.1 Introduction

9.1.2 Viral Constructs Put into Use


9.1.2.1 Replicon-based RNA and DNA vaccines


9.1.2.1.1 The Alphavaccine Platform System - ArV™

9.1.2.1.2 MVA-BN


9.1.2.2 Retroviruses


9.1.2.2.1 The SDSV-platform


9.1.2.3 Lentivirus


9.1.2.3.1 LentiPak™

9.1.2.3.2 LentiVector™/ pEGASUS™


9.1.2.4 Adenoviruses


9.1.2.4.1 Failed Adenovirus Delivery Platforms

9.1.2.4.2 GVAX

9.1.2.4.3 TNFerade™

9.1.2.4.4 INGN-225


9.1.2.5 Adeno-associated viruses


9.1.2.5.1 Failed AAV Delivery Platforms

9.1.2.5.2 Genzyme Acquires AAV vector Technology

9.1.2.5.3 MediGene’s AAV Platform


9.1.2.6 Herpes Simplex Viruses


9.1.2.6.1 DISC-HSV

9.1.2.6.2 ImmunoVEX


9.1.2.7 Poxviruses


9.1.2.7.1 Hi-8™ PrimeBoost™ platform

9.1.2.7.2 PROSTVAC-VF

9.1.2.7.3 Transgene’s MVA Platform

9.1.2.7.4 TroVax


9.1.2.8 Other Poxvirus Systems

9.1.2.9 Baculovirus


9.1.2.9.1 Chimeric virus -like particles (CVLPs)




9.2 Bacterias

9.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies


9.3.1 Introduction

9.3.2 Cell Therapy Strategies


9.3.2.1 Processed Tumor Cells

9.3.2.2 Lysed Tumor Cell Line

9.3.2.3 The Dendritic Cell Strategy that Didn’t Work Out

9.3.2.4 HSPs

9.3.2.5 Provenge™

9.3.2.6 Dendritophages

9.3.2.7 Cell-targeting Antibodies

9.3.2.8 Increase Dendritic Cell Number

9.3.2.9 DCVax®

9.3.2.10 ACTIVATE™



9.4 Synthetic Delivery Systems & Strategies


9.4.1 Introduction

9.4.2 Biotransport™

9.4.3 Biotype®vector

9.4.4 DNAVax Gene Delivery System

9.4.5 FusitAb™

9.4.6 GeneDrug™




List of Boxes

Box 1: Mechanisms Which Tumor Cells Use to Evade an Immune Reaction

Box 2: M-VAX - Business & Market Bakground

Box 3: Gardasil: Business & Market Background

Box 4: TNF in Cancer Treatments




List of Figures

Figure 1: Top 10 Countries in Cancer Vaccine Research

Figure 2: Top 10 Companies’ Clinical Trial Progress in Cancer Vaccine

Figure 3: 2003-2005 Deals & Alliances in Cancer Vaccine

Figure 4: Distribution of Cancer Vaccine Trials in Melanoma

Figure 5: Distribution of Cancer Vaccine Trials in Breast Cancer

Figure 6: Distribution of Cancer Vaccine Trials in Prostate Cancer

Figure 7: Distribution of Cancer Vaccine Trials in Lung Cancer

Figure 8: Distribution of Cancer Vaccine Trials in Colorectal Cancer

Figure 9: Distribution of Cancer Vaccine Trials in Cervical Cancer




List of Tables

Table 1: Companies with Cancer Vaccine Drugs on Market

Table 2: Antigen Classification

Table 3: Platforms Used to Improve Antigen Presentation

Table 4: Cancer Vaccines in Clinical Trials in Combination with Interleukin-2

Table 5: Adjuvants in Cancer Vaccines

Table 6: Synthetic Delivery Systems Deployed in Cancer in General and Cancer Vaccines in Particular

Abstract

Introduction

New approaches in vaccines, such as DNA vaccines, new combination vaccines, new formulations, novel delivery routes, new adjuvants are being explored. In the last three years the cancer vaccine industry has reshaped itself quite considerably. The number of cancer vaccine players has rather decreased than increased, through operational re-prioritizations, M&As and fall outs.

Scope of this report
  • In-depth competitive landscape assessment of the cancer vaccine market
  • Tumor antigen discovery and technologies surrounding it
  • Thorough review of immunomodulating strategies and adjuvants
  • Thorough review of cancer vaccine delivery and technologies surrounding it
  • Progress analysis of six major cancer vaccine indications, including players, drugs, clinical progress and pitfalls
Research and analysis highlights

Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications.

Key reasons to read this report
  • Understand the clinical and strategic challenges to the commercialization of cancer vaccines
  • Assess opportunities and risks for the continued development of cancer vaccines in six major cancer indications.
  • Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development"


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008